title: Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.
authors: M
authors: M
authors: Breccia
authors: M
authors: M
authors: Muscaritoli
authors: F
authors: F
authors: Gentilini
authors: R
authors: R
authors: Latagliata
authors: I
authors: I
authors: Carmosino
authors: F
authors: F
authors: Rossi Fanelli
authors: G
authors: G
authors: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D001786:Blood Glucose / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010879:Piperazines; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D001549:Benzamides; D001786:Blood Glucose; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib